Asset Details
Do you wish to reserve the book?
HER2/neu Testing in Gastric Cancer by Immunohistochemistry: Assessment of Interlaboratory Variation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
HER2/neu Testing in Gastric Cancer by Immunohistochemistry: Assessment of Interlaboratory Variation
Do you wish to request the book?
HER2/neu Testing in Gastric Cancer by Immunohistochemistry: Assessment of Interlaboratory Variation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
HER2/neu Testing in Gastric Cancer by Immunohistochemistry: Assessment of Interlaboratory Variation
2014
Overview
Immunohistochemical (IHC) testing for HER2/neu is becoming the standard of care for guiding adjuvant treatment of gastric carcinoma with trastuzumab.
To assess interlaboratory variation in IHC staining and interpretation across multiple laboratories.
A tissue microarray consisting of 45 cores from 28 gastric cancers was distributed to 37 laboratories for HER2/neu assessment. The IHC results were compared against expert scores at an academic institution and correlated with in situ hybridization results from the originating specimen. Interlaboratory agreement was calculated using Cohen κ statistic.
The survey demonstrated several variations in IHC methods, including the primary antibodies in use. There was excellent agreement among laboratories in HER2/neu(+) (IHC 3(+)) cases (κ = 0.80 ± 0.01) and very good agreement among laboratories in HER2/neu(-) (IHC 0 or 1(+)) cases (κ = 0.58 ± 0.01). Less agreement was observed among laboratories when scoring equivocal (IHC 2(+)) cases (κ = 0.22 ± 0.01). Sensitivity and specificity of HER2/neu IHC were 99% and 100%, respectively, when measured against expert review and consensus score as a reference standard.
There is substantial interlaboratory agreement in the interpretation of HER2/neu IHC despite variability in protocols. Although HER2/neu IHC is a highly sensitive and specific test, primary antibody selection may significantly affect IHC results. Furthermore, gastric tumors require a unique scoring system and expertise in interpretation. Intratumoral heterogeneity has a significant effect on HER2/neu scoring by IHC. Ongoing quality assurance exercises among laboratories will help ensure optimized HER2/neu testing.
Publisher
College of American Pathologists
Subject
/ Aged
/ Analysis
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Cancer
/ Female
/ Humans
/ Immunohistochemistry - methods
/ Immunohistochemistry - statistics & numerical data
/ In Situ Hybridization - methods
/ In Situ Hybridization - statistics & numerical data
/ Male
/ Receptor, ErbB-2 - antagonists & inhibitors
/ Receptor, ErbB-2 - metabolism
/ Stomach Neoplasms - genetics
/ Stomach Neoplasms - metabolism
/ Tissue Array Analysis - methods
/ Tissue Array Analysis - statistics & numerical data
/ Tumors
